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Gossypol is a natural polyphenolic compound 
extracted from the cotton plant (Gossypium species) 
and the tropical tree, Thespesia populnea. In the late 
1960’s after several observations were done on gos-
sypol’s antifertility action in Chinese men, it attracted 
attention of many investigators trying to figure out the 
mechanisms lying beneath this property [1]. It was first 
demonstrated by Tuszynski and Cossu that gossypol 
has anti-proliferative effects against several cancer 
cell lines, the most sensitive of which are melanoma 
and colon carcinoma cells [2]. Although there are 
limited data about the molecular mechanisms induced 
and/or inhibited in gossypol exposed cancer cells, it 
was shown that gossypol induces apoptosis through 
inhibition of antiapoptotic Bcl-2 family members and 
loss of mitochondrial membrane potential and activa-
tion of caspase-3 [3, 4].There are also a number of 
clinical trials that gossypol show promising efficacy 
against some refractory human cancers [5].
Analysis of the enantiomeric ratios in different 
Malvaceae plants has shown an excess of the (+)/(–) 
enantiomer of gossypol (racemic gossypol) in most 
cottonseeds and in Thespesia populnea, with Gos-
sypium barbadense being the main variety with an 
excess of the (–)/(–) enantiomer (AT-101) [6].
The antiproliferative effect of gossypol and its opti-
cal isomers on various human cell lines of reproductive 
and nonreproductive tissue origin was also studied and 
found that the (–)/(–) enantiomer of gossypol (AT-101) 
has more potent cytotoxic effects than the (+)/(–) 
enantiomer. Moreover, the cytotoxic effect of (–)/(–) 
gossypol (AT-101) was even observed in cells made re-
sistant to adriamycin, vinblastin and cisplastin. Current 
investigations on the cisplatin-resistant head and neck 
squamous cell carcinoma (HNSCC) lines (UM-SCC-
5PT and UM-SCC-10BPT) have also demonstrated the 
reversal of cisplatin resistance by AT-101 [6].
Although the mechanism for cytotoxic effect of 
gossypol on cancer cells has been widely studied, 
there is limited data for angiogenic properties of 
gossypol [7–9]. We have previously shown that gos-
sypol potently inhibits some of angiogenic cytokines 
released from hormone- and drug refractory prostate 
cancer cell lines, at clinically achievable doses [10].
Angiogenesis is one of the major steps in the pro-
cess of cancer progression. It has been demonstrated 
that tumor neovascularization strongly correlates with 
the risk of invasion and metastasis in nearly every 
type of human cancer [11]. Recent interest in the 
therapeutic potential of using angiogenesis as a target 
mechanism for anticancer therapy has led to the identi-
fication of various antiangiogenic agents that interfere 
at various stages of angiogenesis. In consideration of 
ovarian cancer, increased angiogenesis is also asso-
ciated with rapid recurrence and decreased survival. 
Molecular-targeted therapeutics may potentially yield 
improvements in long-term disease control, and many 
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such agents are better tolerated than traditional cyto-
toxic drugs [12–14].
In this study, we aimed to compare the effect of 
gossypol enantiomers in OVCAR-3 cancer cells by 
means of cytotoxicity and apoptosis. OVCAR-3 is 
a highly metastatic, drug resistant human ovarian car-
cinoma cell line, and thus it is an ideal model to study 
the effects and mechanisms of various anticancer 
agents [15]. Moreover, to elucidate the underlying 
rationale of anticancer effects of gossypol enantio-
mers, we searched if any difference, by means of their 
effect on angiogenic molecules, exists between two 
enantiomeric forms of gossypol.
MATERIALS AND METHODS
Cell lines and reagents. Human OVCAR-3 ova-
rian cancer cells were obtained from ICLC (Genova, 
Italy). The cells were grown as monolayers in adhe-
rent cell lines and were routinely cultured in RPMI 
1640 supplemented with 10% heat-inactivated 
FBS, 1% L-glutamine, 1% penicillin-streptomycin in 
75 cm2 polystyrene flasks (Corning Life Sciences, UK) 
and maintained at 37 °C in a humidified atmosphere 
with 5% CO2. Growth and morphology were monitored 
and cells were passaged when they had reached 90% 
confluence. Cell culture supplies were obtained from 
Biological Industries (Kibbutz Beit Haemek, Israel). 
Racemic gossypol (98% > purity) was obtained from 
Sigma Chemical Co (USA). AT-101 was a generous gift 
from Ascenta Therapeutics (Nova Scotia, Canada). The 
stock solutions of racemic gossypol and AT-101 were 
prepared in DMSO (10 mM). The final dilutions were 
made immediately before use, and new stock solutions 
were made for each experiment. The DMSO concent-
ration in the assay did not exceed 0.1% and was not 
cytotoxic to the tumor cells. All other chemicals, unless 
mentioned, were purchased from Sigma.
XTT cell viability assay. After verifying cell viabil-
ity using trypan blue dye exclusion test by Cellometer 
auto matic cell counter (Nexcelom Inc.,USA.), cells were 
seeded at approximately 1x104/ well in a final volume 
of 200 μl in 96-well flat-bottom microtiter plates with 
or without various concentrations of drugs. Plates 
were incubated at 37 °C in a 5% CO2 incubator for the 
indicated time periods. At the end of incubation, 100 μl 
of XTT (Roche Applied Science, Mannheim, Germany) 
was added to each well, and plates were incubated at 
37 °C for another 4 hours. Absorbance was measured at 
450 nm against a reference wavelength at 650 nm using 
a microplate reader (Beckman Coulter, DTX 880 Multi-
mode Reader). The mean of triplicate experiments for 
each dose was used to calculate the IC50 values.
Evaluation of apoptosis. Apoptosis was evalua-
ted by an ELISA using Cell Death Detection ELISA Plus 
Kit (Roche Applied Science, Mannheim, Germany) ac-
cording to the instruction manual. The relative amounts 
of mono- and oligonucleosomes generated from the 
apoptotic cells were quantified using monoclonal an-
tibodies directed against DNA and histones by ELISA. 
Briefly, cytoplasmic fractions of the untreated control, 
racemic gossypol and AT-101 treated cells were trans-
ferred onto a streptavidin-coated plate and incubated 
for 2 hours at room temperature with a mixture of 
peroxidase conjugated anti-DNA and biotin labeled 
antihistone. The plate was washed thoroughly, incu-
bated with ABTS, then absorbance was measured at 
405 nm with a reference wavelength at 490 nm (Beck-
man Coulter, DTX 880 Multimode Reader).
Cell treatment and RNA isolation. OVCAR-3 cells 
were treated with either 10 μM of racemic gossypol 
or 3 μM AT-101 (doses that were below IC50 levels of 
both drugs) for 72 h, and then the total RNA from each 
sample was isolated by TridityG (Applichem) followed 
by chloroform according to the manufacturer’s instruc-
tions. Samples were vigorously shaken for 15–20 s 
and were incubated for 15 min at room temperature 
to allow separation of aqueous layer with isopropanol, 
followed by a final wash in 75% ethanol. RNA pellets 
were air-dried and resuspended in RNase free water. 
RNA yield was determined spectrophotometrically by 
measuring the optical density at 260 nm and quality was 
determined by running samples on a 2% agarose gel 
and inspecting for distinct 18S, 28S and tRNA bands, 
indicating lack of degradation. Samples were frozen at 
–80 °C until use in cDNA synthesis.
RT2ProfilerTM human angiogenesis PCR array. 
5 μg of total RNA was reverse transcribed in a final 
reaction mix of 20 μl using RT2 First Strand Kit (Su-
perArray Bioscience) according to the manufacturer’s 
instructions. cDNA was diluted by adding RNase free 
water. The PCR was carried out with a Light Cycler 
480 instrument (Roche Applied Science, Mannheim, 
Germany). For one 96 well-plate of the PCR array, 
2550 μl PCR master mix containing 2x SuperArray 
RT2 qPCR Master Mix and 102 μl of diluted cDNA was 
prepared, and aliquat of 25 μl was added to each well. 
Universal cycling conditions (10 min at 95 °C, 15 s at 
95 °C, 1 min 60 °C for 40 cycles) were used.
Five endogenous control genes beta-2-microglo-
bulin (B2M), hypoxanthine phosphoribosyltransferase 
(HPRT1), ribosomal protein L13a (RPL13A), glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH), and 
β-actin (ACTB) present on the PCR Array were used for 
normalization. Each replicate cycle threshold (CT) was 
normalized to the average CT of 5 endogenous controls 
on a per plate basis. The comparative CT method was 
used to calculate the relative quantification of gene 
expression. The following formula was used to calcu-
late the relative amount of the transcripts in the drugs 
treated samples and the control group, both of which 
were normalized to the endogenous controls: ΔΔCT = 
ΔCT (drugs treated) — ΔCT (control) for RNA samples. 
ΔCT is the log2 difference in CT between the target gene 
and endogenous controls by subtracting the average 
CT of controls from each replicate. The fold change 
for each treated sample was relative to the control 
sample = 2–ΔΔCT.
Sensitivity detection and identification of exp-
ressed genes. PCR Array quantification was based on 
the CT number. CT was defined as 35 for the ΔCT calcula-
222 Experimental Oncology 31, 220–225, 2009 (December)
tion when the signal was under detectable limits. A list 
of differentially expressed genes was identified using 
a 2-tailed t-test. Changes in gene expression between 
drug treated cells and untreated controls were illus-
trated as a fold increase/decrease. The criteria were 
a p value less than 0.05 and a mean difference equal to 
or greater than 3-fold change in expression levels after 
treatment. The statistical calculation was based on the 
web-based program of RT2ProfilerTM PCR Array Data 
Analysis. Alterations in mRNA levels which suited above 
criteria were considered to be up- or down regulated. 
The experiments were repeated three times.
Statistical analysis. All experiments were con-
ducted in triplicate and the results expressed as the 
mean ± SD, with differences assessed statistically with 
p values determined by Student’s t-test.
RESULTS
Both racemic gossypol and AT-101 decreased 
the viability of human OVCAR-3 ovarian carci-
noma cells in a time and dose dependent man-
ner. To evaluate the effects of racemic gossypol and 
AT-101 on the viability of human ovarian cancer cells, 
OVCAR-3 cells were exposed to increasing concen-
trations of racemic gossypol (from 5- to 40 μM) and 
AT-101 (from 1- to 10 μM) for 24, 48 and 72 h, and XTT 
cell viability assay was performed. Both of the drugs 
decreased cell viability in a time- and dose dependent 
manner in OVCAR-3 cells (data not shown). As shown 
in figure 1, there were decreases in cell viability of 22-, 
53-, and 65% in OVCAR-3 cells exposed to 5-, 15-, and 
30 μM of racemic gossypol, respectively, when com-
pared to untreated controls at 72 h. In addition, there 
were decreases in cell viability of 21-, 34-, and 78% in 
OVCAR-3 cells exposed to 2.5-, 5-, and 7.5 μM of AT-
101, respectively, when compared to untreated controls 
at 72 h (Fig. 1). The highest cytotoxicity was observed at 
72 h and IC50 values of racemic gossypol and AT-101 in 
OVCAR-3 cells were calculated from cell viability plots 
and were found to be 16 and 4.2 μM, respectively.
As consistent with the literature, AT-101 was much 
more potent on reducing cell viability of ovarian cancer 
cells as compared to racemic gossypol.
The evidence of apoptosis was more prominent 
in lower doses of AT-101 treated ovarian cancer 
cells as compared to racemic gossypol by DNA 
fragmentation analysis. As a marker of cell death, 
the levels of mono-oligo nucleosome fragments were 
measured using Cell Death Detection Plus Elisa Kit 
(Roche Applied Science, Mannheim, Germany). 
OVCAR-3 cells were treated with increasing concen-
trations of racemic gossypol or AT-101 for 72 h before 
analyzing DNA fragmentations. The results showed 
that when OVCAR-3 cells were exposed to 5, 15, 
and 30 μM of racemic gossypol, an increase in DNA 
fragmentation of 1.6, 2.9 and 7.2 times was observed 
(Fig. 2). However, when OVCAR-3 cells were exposed 
to 2.5, 5 and 7.5 μM AT-101, an increase in DNA frag-
mentation of 1.9, 2.6 and 4.9 times was observed 
(Fig. 2). These results clearly indicate that both of the 
drugs induce apoptosis in a dose- and time dependent 
manner (data not shown).
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Fig. 1. Effect of single racemic gossypol and AT-101 on viability 
of OVCAR-3 cells at 72 h in culture. The data represents the mean 
of three different experiments (p < 0.05). The error bars represent 
the standard deviations, and where they are not seen, they are 
smaller than the thickness of the lines on the graphs.
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Fig. 2. Apoptotic effects of single racemic gossypol and AT-
101 in OVCAR-3 cells through DNA fragmentation analyses. 
The data represents the mean of three different experiments 
(p < 0.05). The error bars represent the standard deviations, and 
where they are not seen, they are smaller than the thickness of 
the lines on the graphs.
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Comparison of angiogenic molecules of 
OVCAR-3 cells treated with either racemic gossypol 
or AT-101.  To evaluate the effect of racemic gossypol and 
AT-101 on the angiogenic molecules in OVCAR-3 cells, 
we used RT2ProfilerTM Human Angiogenesis PCR Array 
(SuperArray Bioscience). According to PCR array data, 
both of the drugs altered the expression profiles of some 
important angiogenic factors in OVCAR-3 cells as listed 
in Table 1. Changes in gene expression between drug 
treated cells and untreated controls were illustrated as 
a fold increase/decrease, and ≥ 3 fold change was ac-
cepted as significant. While exposure of racemic gossypol 
(10 μM) caused down regulation of fibroblast growth 
factor 2 (FGF2), fibroblast growth factor receptor 3 
(FGFR3), inhibitor of DNA binding 1, dominant negative 
helix-loop-helix protein (ID1), inhibitor of DNA binding 3, 
dominant negative helix-loop-helix protein (ID3), integrin 
alpha V (ITGAV), integrin beta 3 (ITGB3), midkine (MDK), 
matrix metalloproteinase 2 (MMP2), MMP9, plexin do-
main containing 1 (PLXDC1), transforming growth factor, 
beta 2 (TGFB2), TGFBR1, thrombospondin 1 (THBS1), 
THBS2 genes, AT-101 (3 μM) additionally caused down 
regulation of V-akt murine thymoma viral oncogene ho-
molog 1 (AKT1), EPH receptor B4 (EPHB4), heparanase 
(HPSE), laminin, alpha 5 (LAMA5), neuropilin 1 (NRP1), 
tumor necrosis factor (TNF), tumor necrosis factor alpha-
induced protein 2 (TNFAIP2), thymidine phosphorylase 
(TYMP), vascular endothelial growth factor A (VEGFA) 
and C genes apart from racemic gossypol. Furthermore, 
exposure of AT-101 caused to up-regulation of some 
genes that take role in inhibiting angiogenesis or inducing 
apoptosis (Table 1).
Table 1. Changes in mRNA levels of angiogenesis-related genes in 
OVCAR-3 cells exposed to racemic gossypol or AT-101. Changes 
≥ 3 fold was accepted as significant according to web-based program of 
RT2ProfilerTM PCR Array Data Analysis.
Racemic gossypol AT-101
Gene Fold change Gene Fold change
FGF2 –5.3 AKT1 –9.1
FGFR3 —3.9 ANGPT2 +7.2
ID1 –4.4 BAI1 +5.9
ID3 –3.6 EPHB4 –16.5
ITGAV –8.8 FGF2 –7.5
ITGB3 –4.7 FGFR3 –5.7
MDK –3.4 HGF –3.2
MMP2 –3.7 HPSE –5.5
MMP9 –4.1 ID1 –15.8
PLXDC1 –4.5 ID3 –18.0
TGFB2 –4.5 ITGAV –10.8
TGFBR1 –8.0 ITGB3 –4.9
THBS1 –6.0 LAMA5 –8.1
THBS2 –6.5 JAG1 +3.5
VEGFC –13.0 LECT1 +4.8
MDK –22.1
MMP2 –4.2
MMP9 –9.9
NOTCH4 +26.0
NRP1 –7.8
PLXDC1 –5.9
TGFB2 –4.9
TGFBR1 –10.9
THBS1 –14.7
THBS2 –8.1
TIMP1 +25.9
TIMP2 +16.8
TNF –15.2
TNFAIP2 –5.7
TYMP –15.3
VEGFA –11.3
VEGFC –30.7
DISCUSSION
Gossypol is mainly found in two enantiomeric forms 
in nature: racemic form and (–)/(–) gossypol (AT-101). 
There is a body evidence that AT-101 was more potent 
than racemic form, although both enantiomeric forms 
of gossypol have cytotoxic and apoptotic effect for 
many types of cancer cells [16, 17]. Our study has 
demonstrated that the efficacy of two enantiomers 
was different from each other, and AT-101 was much 
more potent than gossypol, not only in cytotoxicity and 
apoptosis, but also by down-regulation of some crucial 
angiogenic molecules in OVCAR-3 cells.
Of angiogenic molecules that have been down-
regulated by gossypol enantiomers were members 
of inhibitor of differentiation (ID), since upregulation 
of ID-1 is associated with advanced tumor stage and 
poor prognosis in ovarian cancer patients. Therefore 
ID-1 is one emerging targets for cancer treatment [18]. 
Furthermore, ID-3 as an important signaling molecule 
in vascularization may also serve as a therapeutic 
target in neovascularization [19]. Both racemic gos-
sypol and AT-101 caused 4.4 and — 15.8 fold down-
regulation on mRNA level of ID-1 respectively, whereas 
a –3.6 and 18 fold down regulation was observed in 
ID-3 (Table 2).
Table 2. Fold changes in mRNA levels of genes induced by both racemic 
gossypol and AT-101 treatment.
Gene Racemic gossypol AT-101
FGF2 –5.3 –7.5
FGFR3 –3.9 –5.7
ID1 –4.4 –15.8
ID3 –3.6 –18.0
ITGAV –8.8 –10.8
ITGB3 –4.7 –4.9
MDK –3.4 –22.1
MMP2 –3.7 –4.2
MMP9 –4.1 –9.9
PLXDC1 –4.5 –5.9
TGFB2 –4.5 –4.9
TGFBR1 –8.0 –10.9
THBS1 –6.0 –14.7
THBS2 –6.5 –8.1
VEGFC –13.0 –30.7
Heparin binding activity growth factors also show 
potent angiogenic properties, and their up-regulation 
is associated with a broad spectrum of mitogenic 
and angiogenic activities in some malignant tumors, 
including ovarian cancer [20]. Heparin binding activity 
growth factors (bFGF-2 and FGFR-3 and MDK) were 
down-regulated by both enantiomeric forms of gossy-
pol; however the down regulation was much more evi-
dent in AT-101 exposure (Table 2). [21–23]. Moreover 
TGF-β2 and its receptors were also down regulated by 
both racemic gossypol and AT-101 [24].
VEGF has been correlated with poor disease-free 
survival and overall survival in patients with early or 
advanced stage ovarian cancer [25, 26]. Over exp-
ression of VEGF mRNA in the OVCAR-3 has been 
demonstrated previously. AT-101 caused a 30.7 fold 
decrease in VEGF C mRNA levels, while racemic gos-
sypol resulted in only 13.0 fold decline. AT-101, alone, 
caused a –11.3 fold decrease in mRNA levels of VEGF A 
apart from racemic form.
Invasion and metastasis also require degrada-
tion of the basement membrane by members of the 
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MMP family proteins. MMP-2 and MMP-9 have been 
suggested to be critical in the metastatic process 
of ovarian cancer since they can degrade collagen 
IV [27]. The mRNA levels of these genes were down 
regulated by more than 3 fold by both racemic gos-
sypol and AT-101.
EPHB2/B4 has been reported as a biomarker with 
negative prognostic value in ovarian carcinoma [28, 29]. 
AT-101 alone caused to down-regulate EPBH4 gene 
(16.5 fold decrease) in OVCAR-3 cells. mRNA level of 
LAMA-5 was downregulated 8.1 fold. In many types 
of cancer, LAMA-5 has been observed to be highly 
expressed, implying that it is possible candidate for 
targeting angiogenesis in ovarian cancer [30].
Notch homolog 4 (NOTCH4), Angiopoietin 2 
(ANGPT2), Brain-specific angiogenesis inhibitor 
1(BAI1), Tissue inhibitor of metalloproteinase (TIMP1) 
and TIMP2 have been up-regulated significantly by 
26.0, 7.2, 5.9, 10.9, and 14.7 fold respectively by 
AT-101 treatment. Up-regulation of these genes was 
shown to be associated with the inhibition of angio-
genesis in cancer cells. For example activation of 
NOTCH4 modulates switching on angiogenesis [31]. 
ANGPT2 encodes a protein that disrupts the ability 
of vascular remodeling of angioprotein 1 and causes 
endothelial cell death [32]. BAI1 is an inhibitor of 
angiogenesis [33]. The activation of TIMPs results in 
inhibition of constructing new blood vessels [34].
As a conclusion, the efficacy of two gossypol 
enantiomers in OVCAR-3 cells showed distinction. 
AT-101 was much more potent than racemic gossypol, 
not only by means of cell death and apoptosis, but 
also by modulation of angiogenic molecules released 
from OVCAR-3 cells. These preliminary data highlights 
a possible role for future clinical trials with the potent 
form of gossypol enantiomer: AT-101. However, our 
study has some important limitations, since we have 
not yet obtained either in vivo results or studies with 
endothelial cells, which will certainly be very helpful in 
supporting our preliminary results. Further in-depth 
investigations should be done in xenograft models to 
confirm the efficacy and role of gossypol enantiomers 
in cancer treatment.
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